Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hepatitis b: experimental combo aims to silence the virus

NCT ID NCT05612581

Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested two experimental drugs, tobevibart and elebsiran, alone or with standard treatments, in 33 adults with chronic hepatitis B. The goal was to see if these combinations could safely suppress the virus and reduce hepatitis B surface antigen levels. The study is part of a larger effort to find better treatments for this long-term liver infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Tobevibart (VIR-3434) and Elebsiran (VIR-2218) injections, plus standard oral tenofovir and peginterferon
What this could lead to
If successful, this could point toward a more effective combination therapy to control chronic hepatitis B and reduce the need for lifelong medication.
What could go wrong
This is an early-phase trial with only 33 participants, so results may not apply broadly. The treatments may not achieve lasting virus suppression or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

33 people

The number who actually took part.

Started

May 2023

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 66 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female ages 18 or older * Chronic HBV infection for \>/= 6 months * Chronic HBV infection defined as a positive serum HBsAg, HBV DNA, or HBeAg on 2 occasions at least 6 months apart based on previous or current laboratory documentation * STRIVE: HBeAg positive or negative, HBV DNA \> 2,000 IU/mL, ALT \> ULN and ≤ 5x ULN * THRIVE: Must be/have the following, within the 1-year period prior to screening: HBeAg negative, HBV DNA ≤ 2,000 IU/mL, ALT ≤ ULN Exclusion Criteria: * Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation * History of clinically significant liver disease from non-HBV etiology * History or current evidence of hepatic decompensation * Co-infection with human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV) or hepatitis E virus (HEV). * History or clinical evidence of alcohol or drug abuse * STRIVE and THRIVE: Significant fibrosis or cirrhosis * STRIVE and THRIVE: History of immune complex disease * STRIVE and THRIVE: History of autoimmune disorder * STRIVE and THRIVE: History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434 * STRIVE: Prior NRTI or PEG-IFN therapy * STRIVE: History of known contraindication to any interferon product * THRIVE: Prior NRTI therapy \< 24 weeks of study or any prior PEG-IFN therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis B, chronic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis B, chronic

Contacts and locations

Locations

  • Investigative Site

    Clichy, 92110, France

  • Investigative Site

    Nice, 06200, France

  • Investigative Site

    Rennes, 35000, France

  • Investigative Site

    Toulouse, 31000, France

  • Investigative Site

    Hong Kong, Sha Tin, Hong Kong

  • Investigative Site

    Hong Kong, Hong Kong

  • Investigative Site

    Chisinau, MD 2025, Moldova

  • Investigative Site

    Bucharest, 021105, Romania

  • Investigative Site

    Busan, 49241, South Korea

  • Investigative Site

    Seoul, 5505, South Korea

  • Investigative Site

    Yangsan, 50612, South Korea

  • Investigative Site

    Glasgow, G4 0SF, United Kingdom

  • Investigative Site

    London, EC1A 7BE, United Kingdom

  • Investigative Site

    London, SE5 9RS, United Kingdom

  • Investigative Site

    Manchester, M8 5RB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.